Welcome!

News Feed Item

MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience Demonstrate Clinical And Cost Effectiveness Of EpiFix Allograft For Treatment Of Hard-to-Heal Wounds

EpiFix® is shown to promote rapid healing and return to function for patients and provide a potential for significant cost savings.

MARIETTA, Ga., April 23, 2014 /PRNewswire/ -- EpiFix®, dehydrated human amnion/chorion membrane (dHACM) allografts, were shown to be clinically and cost effective in the treatment of multiple hard-to-treat wounds like diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs), according to data and case experiences being presented at the Spring Symposium on Advanced Wound Care, the leading national wound healing conference now in its 27th year.  The symposium begins today, April 23, 2014, and concludes on April 27, 2014.

"We are pleased that two abstracts highlighting EpiFix® allografts were selected for oral presentation and one of them, authored by Charles M. Zelen, DPM, FACFAS, FACFAOM, FAPWCA; Thomas E. Serena MD, FACS and Robert J. Snyder, DPM, MSc, CWS, was selected as 3rd place for Best Oral Abstract," said Parker H. "Pete" Petit, CEO of MiMedx Group, Inc.  (NASDAQ: MDXG).

"Clinically, EpiFix® is associated with more rapid healing and prevention of longer term complications including infection and amputation," said Dr. Stephen Bergquist, Medical Director for Jackson-Madison County Hospital.  "From the cost-of-care perspective, EpiFix requires the use of fewer grafts leading to overall cost savings," he continued.

Abstracts presenting EpiFix® studies and cases are:

  • A Prospective, Randomized, Comparative Study of Weekly vs. Bi-weekly Application of Dehydrated Human Amnion/Chorion Membrane Allograft in the Management of Diabetic Foot Ulcers (Abstract #CR_055, Zelen, Serena, Snyder) demonstrated in a 12-week study period of 40 patients with a mean time to complete healing of 2.4 weeks for weekly application of EpiFix® vs. 4.1 wks for biweekly application of EpiFix®.  This shows using EpiFix® weekly heals DFUs almost twice as fast as biweekly applications of EpiFix®. Overall complete heal rate with EpiFix® in both arms was 92.5% (37/40) at 12 weeks.

 

  • A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Dehydrated Human Amniotic Membrane and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers (Abstract #CS_139,Serena,  Fetterolf , Harris, Doner, Patel, Connell, DeMarco, LE, McConnell , Lullove, Taffe.) 90 patients were enrolled to date in this ongoing trial. At time of interim analysis 68 patients had completed the study: 44 ulcers were randomized to receive dHACM (1 or 2 applications) and 24 received SOC alone. Outcomes were similar within the dHACM group.  At 4 weeks, 63.6% of wounds in the dHACM  group, and 25.0% of the standard of care group demonstrated greater than 40% wound closure at 4 weeks (p=0.0023). After 4 weeks ulcers treated with dHACM had reduced by 48.9% vs 12.0% for those treated with SOC only, p=0.003.

 

  • Treatment of Stage III and Stage IV Pressure Ulcers with Dehydrated Human Amnion/Chorion Membrane (Abstract #CS_014, Bergquist) evaluated the clinical and cost effectiveness of dHACM allografts as a treatment for Stage III and IV pressure ulcers (PUs).   In Stage III cases and Stage IV cases,  PUs of varying sizes were completely healed within weeks (from 1 week for  Stage III PUs with wound size of 8.6cm2 and 2.53 cm2, to 8 weeks for a Stage IV PU with an initial wound size of 9.2 cm2 ). Cost effectiveness of dHACM for treatment of PUs was influenced by increased healing rates, velocity of healing and subsequent reduction in risk for complications.  Wound size-appropriate grafts further reduce waste and cost per treatment. 

 

  • Human Amniotic Membrane Allograft to Treat Diabetic Foot Ulcers with Exposed Bone and Tendon   (Abstract# CS_117 Pougatsch, Shum, Belczyk, Rogers) 5 consecutive diabetic neuropathic patients exhibiting wounds with exposed bone and tendon were treated with EpiFix® with the intent to gain as much coverage over the exposed deep structures in as little time as possible in preparation for split-thickness skin grafting. All 5 patients had sufficiently developed granulation tissue overlying bone and tendon structures and were ready for split-thickness skin grafting in an average of 15 days (range 9-22). 4 patients healed the split-thickness skin grafts.

 

"These data support our previously published studies relating to the significant role for EpiFix® in advanced wound care," said Bill Taylor, President and COO of MiMedx. MiMedx is the leading developer and manufacturer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane.

MiMedx is exhibiting at the conference (booth 1506), and will host In-Booth Education with speakers Steve Bergquist, MD presenting on 'Complex wounds and pressure ulcer treatment with EpiFix', and Donna Becker, MSN, ACNP-BC who will discuss 'Clinical experiences with dHACM.'  Drs. Robert Snyder, Chuck Zelen, Matthew Garoufalis and Thomas Serena will be presenting about Wound Regeneration at a Company-sponsored symposium.

About EpiFix®

EpiFix® is a human amniotic allograft tissue offering uniquely processed through the Company's proprietary PURION® Process. EpiFix® dehydrated human amnion/chorion membrane (dHACM) can reduce inflammation and reduce scar tissue formation for enhanced healing. With a variety of sizes available, EpiFix® minimizes graft waste.  The Company's PURION® Process combines cleaning, dehydration and sterilization, making EpiFix® a safe, sterilized tissue that may be stored at ambient conditions for up to 5 years.

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 225,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"We are still a relatively small software house and we are focusing on certain industries like FinTech, med tech, energy and utilities. We help our customers with their digital transformation," noted Piotr Stawinski, Founder and CEO of EARP Integration, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I think DevOps is now a rambunctious teenager – it’s starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We've been engaging with a lot of customers including Panasonic, we've been involved with Cisco and now we're working with the U.S. government - the Department of Homeland Security," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
In the enterprise today, connected IoT devices are everywhere – both inside and outside corporate environments. The need to identify, manage, control and secure a quickly growing web of connections and outside devices is making the already challenging task of security even more important, and onerous. In his session at @ThingsExpo, Rich Boyer, CISO and Chief Architect for Security at NTT i3, discussed new ways of thinking and the approaches needed to address the emerging challenges of security i...
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I will be talking about ChatOps and ChatOps as a way to solve some problems in the DevOps space," explained Himanshu Chhetri, CTO of Addteq, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
"We are an IT services solution provider and we sell software to support those solutions. Our focus and key areas are around security, enterprise monitoring, and continuous delivery optimization," noted John Balsavage, President of A&I Solutions, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, discussed the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
The financial services market is one of the most data-driven industries in the world, yet it’s bogged down by legacy CPU technologies that simply can’t keep up with the task of querying and visualizing billions of records. In his session at 20th Cloud Expo, Karthik Lalithraj, a Principal Solutions Architect at Kinetica, discussed how the advent of advanced in-database analytics on the GPU makes it possible to run sophisticated data science workloads on the same database that is housing the rich...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
"We want to show that our solution is far less expensive with a much better total cost of ownership so we announced several key features. One is called geo-distributed erasure coding, another is support for KVM and we introduced a new capability called Multi-Part," explained Tim Desai, Senior Product Marketing Manager at Hitachi Data Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
FinTechs use the cloud to operate at the speed and scale of digital financial activity, but are often hindered by the complexity of managing security and compliance in the cloud. In his session at 20th Cloud Expo, Sesh Murthy, co-founder and CTO of Cloud Raxak, showed how proactive and automated cloud security enables FinTechs to leverage the cloud to achieve their business goals. Through business-driven cloud security, FinTechs can speed time-to-market, diminish risk and costs, maintain continu...